中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 11
Nov.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(11): 2558-2561

Association between liver fibrosis progression and endothelin-1/nitric oxide in patients with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.11.015
  • 1.

    Graduate School, Guangxi University of Chinese Medicine, Nanning 530001, China

  • 2.

    Department of Liver Disease, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China

Research funding:

Guangxi Science Foundation Project (AB18221009);

High-Level Talent Team Cultivation Project of the Qihuang Project of Guangxi University of Traditional Chinese Medicine (2021007);

Guangxi First-Class Discipline Construction Project in 2019 (2019XK139);

Traditional Chinese Medicine Inheritance and Innovation Talents Training Platform Construction Project in 2019 (National Traditional Chinese Medicine Education Letter No.41, 2019);

National Natural Science Foundation of China (81473532)

  • Received Date: 2021-03-13
  • Accepted Date: 2021-04-25
  • Published Date: 2021-11-20
    Abstract
  •   Objective  To investigate whether the progression of liver fibrosis affects endothelial function in patients with nonalcoholic fatty liver disease (NAFLD), and to early identify the warning of cardiovascular diseases caused by endothelial dysfunction by liver fibrosis progression.  Methods  A total of 280 patients who attended the outpatient service or were hospitalized in Department of Liver Disease, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, from April 2019 to October 2020 were enrolled, and they were diagnosed with fatty liver disease by ultrasound and met the diagnostic criteria for NAFLD. General information and related serological markers were collected and recorded. FibroTouch technique was performed for the NAFLD patients diagnosed by ultrasound to record their fat attenuation parameter (FAP) and liver stiffness measurement (LSM), and according to LSM, the patients were divided into non-progressive fibrosis group (239 patients with LSM < 11 kPa) and progressive fibrosis group (41 patients with LSM ≥11 kPa) to analyze the association between liver fibrosis progression and endothelin-1 (ET-1)/nitric oxide (NO) in NAFLD. The t-test or the Mann-Whitney U test was used for comparison of continuous data between two groups, and the Spearman method was used for correlation analysis.  Results  There were no significant differences between the non-progressive fibrosis group and the progressive fibrosis group in the expression levels of ET-1(Z=-0.190, P=0.849) and NO(Z=-1.509, P=0.131), and there were significant differences between the two groups in body mass index (BMI), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) (Z=-3.977, -4.162, -3.471, -3.201, -3.202, and -3.311, all P < 0.05). The Spearman analysis showed that LSM was not correlated with ET-1, NO, and NO/ET-1 (rs=-0.046, 0.086, and 0.104, all P > 0.05). Further analysis of the correlation of ET-1 and NO with each index showed that ET-1 was not correlated with age, NO, ALT, AST, GGT, total cholesterol, TG, HDL-C, low-density lipoprotein cholesterol (LDL-C), FAP, and BMI (rs=-0.017, 0.054, -0.067, -0.016, -0.031, 0.004, 0.051, -0.084, -0.030, 0.080, and 0.044, all P > 0.05), and NO was not correlated with age, ET-1, ALT, AST, GGT, total cholesterol, TG, HDL-C, LDL-C, FAP, and BMI (rs=0.004, 0.054, 0.011, 0.052, 0.004, -0.051, -0.052, -0.012, -0.076, -0.013, and -0.021, all P > 0.05).  Conclusion  This study shows that liver fibrosis progression in NAFLD has no impact on ET-1 and NO, suggesting that fibrosis progression may have no influence on endothelial function.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    MIKOLASEVIC I, ORLIC L, FRANJIC N, et al. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease-Where do we stand?[J]. World J Gastroenterol, 2016, 22(32): 7236-7251. DOI: 10.3748/wjg.v22.i32.7236.
    [2]
    VILLANOVA N, MOSCATIELLO S, RAMILLI S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease[J]. Hepatology, 2005, 42(2): 473-480. DOI: 10.1002/hep.20781.
    [3]
    CHU WW, GUAN LL, HUANG DH, et al. Correlation between plasma endothlin-1 level and insulin resistance in impaired glucose regulation patients with nonalcoholic fatty liver disease[J]. Zhejiang Med J, 2018, 40(6): 600-602. DOI: 10.12056/j.issn.1006-2785.2018.40.6.2016-2083.

    褚韦韦, 官莉莉, 黄迪华, 等. 糖调节异常合并非酒精性脂肪性肝病患者血内皮素-1与胰岛素抵抗的相关性研究[J]. 浙江医学, 2018, 40(6): 600-602. DOI: 10.12056/j.issn.1006-2785.2018.40.6.2016-2083.
    [4]
    DINH QN, DRUMMOND GR, SOBEY CG, et al. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension[J]. Biomed Res Int, 2014, 2014: 406960. DOI: 10.1155/2014/406960.
    [5]
    Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Guidelines for management of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2010, 26(2): 120-124. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201903008.htm

    中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 临床肝胆病杂志, 2010, 26(2): 120-124. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201903008.htm
    [6]
    Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient elastography detecting liver fibrosis: A 2018 update[J]. Chin J Hepatol, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
    [7]
    ZHU HM, WANG QY. Advances in the diagnosis and treatment of nonalcoholic fatty liver disease-related liver fibrosis[J]. J Clin Hepatol, 2020, 36(1): 178-181. DOI: 10.3969/j.issn.1001-5256.2020.01.042.

    朱红梅, 王勤英. 非酒精性脂肪性肝病肝纤维化的诊断和治疗进展[J]. 临床肝胆病杂志, 2020, 36(1): 178-181. DOI: 10.3969/j.issn.1001-5256.2020.01.042.
    [8]
    JIANG YZ, NIE HM, WANG R. Research advances in the pathogenesis of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2019, 35(11): 2588-2591. DOI: 10.3969/j.issn.1001-5256.2019.11.044.

    姜煜资, 聂红明, 汪蓉. 非酒精性脂肪性肝病的发病机制[J]. 临床肝胆病杂志, 2019, 35(11): 2588-2591. DOI: 10.3969/j.issn.1001-5256.2019.11.044.
    [9]
    BYRNE CD, TARGHER G. NAFLD: A multisystem disease[J]. J Hepatol, 2015, 62(1 Suppl): s47-s64. DOI: 10.1016/j.jhep.2014.12.012.
    [10]
    WANG YH, GAO Y. Research progress in diagnosis and treatment of non-alcoholic fatty liver disease combinated with type 2 diabetes mellitus[J]. J Jilin Univ(Med Edit), 2020, 46(6): 1324-1331. DOI: 10.13481/j.1671-587x.20200634.

    王雨涵, 高影. 非酒精性脂肪性肝病并发2型糖尿病诊断和治疗的研究进展[J]. 吉林大学学报(医学版), 2020, 46(6): 1324-1331. DOI: 10.13481/j.1671-587x.20200634.
    [11]
    ANSTEE QM, MANTOVANI A, TILG H, et al. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7): 425-439. DOI: 10.1038/s41575-018-0010-0.
    [12]
    HENSON JB, SIMON TG, KAPLAN A, et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2020, 51(7): 728-736. DOI: 10.1111/apt.15660.
    [13]
    DEGERTEKIN B, OZENIRLER S, ELBEG S, et al. The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis[J]. Dig Dis Sci, 2007, 52(10): 2622-2628. DOI: 10.1007/s10620-006-9147-8.
    [14]
    KARDUM D, FABIJANIĆ D, LUKIĆ A, et al. Correlation of endothelin-1 concentration and angiotensin-converting enzyme activity with the staging of liver fibrosis[J]. Coll Antropol, 2012, 36(2): 413-418. DOI: 10.1016/j.anthro.2012.05.004.
    [15]
    IWAKIRI Y, KIM MY. Nitric oxide in liver diseases[J]. Trends Pharmacol Sci, 2015, 36(8): 524-536. DOI: 10.1016/j.tips.2015.05.001.
    [16]
    TSOCHATZIS EA, NEWSOME PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care[J]. Lancet Gastroenterol Hepatol, 2018, 3(7): 509-517. DOI: 10.1016/S2468-1253(18)30077-3.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (500) PDF downloads(49) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return